OpenEvidence Raises $250M at $15B, 25% Above January's $12B Mark and Weighing Sale | AI Weekly
OpenEvidence, an AI clinical search tool used by 40% of US physicians, raised $250 million at a $15 billion valuation — a 25% jump from January — and is now considering acquisition offers instead of going public. The company's hitting roughly $300 million in annual revenue.
- OpenEvidence closed a $250M funding round at $15B valuation, doubling its January $12B mark in nine months
- The company commands 40% of the US physician market and generated ~$300M annualized revenue by mid-2026
- Founders are actively exploring acquisition interest rather than pursuing an IPO path
OpenEvidence just raised $250 million at a $15 billion valuation, marking a 25% jump from its $12 billion valuation in January 2026. The AI clinical search engine has become essential infrastructure in American medicine — about 40% of US physicians use it. This is the company's second valuation doubling in nine months, which is genuinely fast for any company, let alone one in the notoriously slow-moving healthcare space.
The real news here is that the founders aren't necessarily committed to the IPO path. They're actively entertaining acquisition offers, which suggests either they've hit a natural ceiling for growth or they see more value in selling to a larger player than in staying independent. Given the competitive dynamics in healthcare AI, that calculation makes sense — a big tech company or healthcare conglomerate could integrate OpenEvidence into existing platforms and reach.
Revenue tells the story of why buyers are circling. Sacra estimates OpenEvidence hit roughly $300 million in annualized revenue by mid-2026. That's an absurdly fast ramp for a healthcare tool. Most vertical AI companies take years to reach that kind of scale. At this valuation and revenue run rate, the company is trading at about 5x revenue — reasonable for a high-growth SaaS business but not the 10-20x multiples you see with earlier-stage AI darlings. That gap between valuation and revenue suggests the market sees real limits ahead, which probably explains why the founders are open to selling.